terventions, these studies have primarily been limited to single or small collections of centers. [4] [5] [6] [7] [8] [9] Demonstration of similar reductions on a larger scale in the United States have been limited to evaluations of central line-associated MRSA bloodstream infections (BSIs) in intensive care units. 10 Large decreases in MRSA BSIs have also been reported in England following a government mandate. 11, 12 National data describing changes in incidence in US acute care hospitals are not available. Therefore, to better characterize changes in MRSA infections in the United States, we used a populationbased surveillance system to evaluate the incidence of invasive health careassociated MRSA infections from 2005 through 2008.
METHODS

Surveillance Population
Data on invasive MRSA infections were collected from facilities participating in the CDC's Emerging Infections Program/Active Bacterial Core surveillance system. This is an active population-based surveillance program that since mid-2004 has received laboratory reports on invasive MRSA in 9 geographically diverse metropolitan areas, covering a population of approximately 15 million persons in 2008, including the state of Connecticut (estimated population 3.5 million); the Atlanta, Georgia, metropolitan area (Clayton, Cobb, DeKalb, Douglas, Fulton, Gwinnett, Newton, and Rockdale counties; estimated population 3.8 million); the San Francisco Bay area, California (Alameda, Contra Costa, and San Francisco counties; estimated population 3.3 million); the Denver, Colorado, metropolitan area (Arapahoe county; estimated population 554 000); the Portland, Oregon, metropolitan area (Clackamas, Multnomah, Washington counties; estimated population 1.6 million); Monroe County, New York (estimated population 733 000); Baltimore City, Maryland (estimated population 637,000); Davidson County, Tennessee (estimated population 626 000); and Ramsey County, Minnesota (estimated population 501 000). This analysis included only population catchment areas participating in the surveillance program continuously since January 2005.
Definitions
Cases of invasive MRSA infection were defined as isolation of MRSA from a normally sterile body site in a resident of the surveillance area during [2005] [2006] [2007] [2008] . Cases were identified from microbiology reports provided by all clinical microbiology laboratories in acutecare facilities and reference laboratories that receive specimens for residents of the areas under surveillance. Surveillance personnel complete a standard case report form using data abstracted from inpatient and outpatient medical records. A more detailed description of the methods used for the project is available elsewhere. 13 For analysis, cases of invasive MRSA infection were classified into mutually exclusive categories. Cases were considered hospital-onset if the clinical culture from which MRSA was isolated was obtained on or after hospital day 4 (day of admission counted as day 1); were considered health care-associated community-onset if MRSA was isolated from an outpatient or 3 or fewer calendar days after an admission but recent exposure to health care is documented for the case; and were considered communityassociated if MRSA was isolated from an outpatient or 3 or fewer calendar days after an admission and no recent health care exposure is documented. The 3-calendar-day period is currently recommended as a proxy for laboratory-based categorization of multidrug-resistant organisms such as MRSA into hospital-onset and community-onset groups.
14 Recent health care exposures included presence of a central venous catheter at hospital admission or documentation of at least 1 of the following in the prior year: an overnight stay in an acute care or long-term care facility, receipt of dialysis, or surgery. For this analysis, documented history of either infection or colonization with MRSA was not sufficient to categorize cases as health care associated.
Cases were also categorized into infection syndromes based on diagnoses present in the medical records. Syndromes were classified as pneumonia or empyema, skin and soft tissue infections, bone and joint infections, urinary tract infections, endocarditis, or "other." Cases were categorized as BSIs if there was a positive blood culture for MRSA. Each case could represent more than one infection syndrome.
Human Subjects Considerations
The invasive MRSA surveillance project underwent ethical review at the CDC and was determined to be a nonresearch activity. It was therefore not subject to a review by a CDC institutional review board. This activity was also evaluated independently at each program site and either deemed a public health assessment or human subjects research and approved by local review boards when applicable.
Statistical Analysis
Because the focus of this evaluation was on health care-associated incidence rates, this analysis included only hospital-onset and health care-associated community-onset infections. Annual invasive MRSA infection pooled mean incidence was calculated by epidemiological category (ie, hospital-onset and health care-associated communityonset) for all sites combined; rates were also stratified for age, sex, and racespecific incidence rates by year and epidemiological category.
Rates were calculated using US census estimates of the surveillance area population for each year as the denominator. Denominators for annual pooled mean incidence rates of invasive MRSA infections among patients undergoing dialysis were calculated using data from the US Renal Data System (ie, the point prevalence of dialysis patients in the Medicare End-Stage Renal Disease program on December 31, 2004 December 31, , 2005 December 31, , 2006 December 31, , or 2007 ; the numerator included patients who had dialysis within 1 year of their invasive infection. For each incidence rate, exact 95% confidence intervals (CIs) were calculated using a Poisson distribution.
Changes in incidence over time, stratified by epidemiological category, were preliminarily assessed using a Poisson regression model among Emerging Infections Program sites. The outcome variable was number of invasive MRSA infections, the population of the catchment area was the offset, and time (year), as a continuous variable, was the predictor. To estimate the overall rate of change for all sites from 2005 through 2008, a hierarchical modeling method was used (hereafter referred to as the modeled rate). Because both the 2005 invasive MRSA infection incidence (intercepts) and the temporal trends (slopes for year) varied by site, a mixed model was fitted to include 2 additional sources of variation, the intercept and the slope for year at each site, which were included in the model as random effects.
Models were fitted for all invasive MRSA infections initially and subsequently for MRSA BSIs. The models for all invasive MRSA and for MRSA BSIs were adjusted for 2 site-level variables, age (ie, proportion Ͼ65 years) and race (ie, proportion black race). When using different dichotomous age break points (ie, Յ18 vs Ͼ18 years, and Յ40 vs Ͼ40 years) in separate models, the change estimate did not differ substantially from the estimate generated by the primary model. In addition, including age as a continuous variable (without race in the model) did not change the point estimates. Including age as a continuous variable with race in the same model could not be accomplished do to limited power in the resulting individual strata. Therefore, we chose to include both age and race as dichotomous variables. Because the highest incidence of invasive MRSA occurred in patients aged 65 years or older, we used this as our age break point in the final model.
The yearly decrease in dialysis patients was also modeled using a similar hierarchical modeling method; however, because race and age information was not available for the dialysis denominator, we were unable to adjust these models for these variables. Point estimates and 95% CIs for the yearly percent change were determined using each model. P values Ͻ.05 were considered statistically significant. These final models were also used to determine the adjusted incidence for each epidemiology category for each year studied. Forest plots were constructed to demonstrate the differences in crude yearly percent changes and 95% CIs for each site. Analyses were performed using Stata software version 9.2 (Stata Corp, College Station, Texas) and SAS software version 9.2 (SAS Institute Inc, Cary, North Carolina).
RESULTS
Case Characteristics
O v e r a l l , E m e r g i n g I n f e c t i o n s Program/Active Bacterial Core surveillances sites reported 21 503 cases of invasive MRSA infections for the years 2005 through 2008. Of these, 21 333 reports (99%) allowed categorization into epidemiological classes: 12 235 infections (57%) were health care-associated community-onset, 5273 (25%) were hospital-onset, and 3825 (18%) were communityassociated. The percentage of overall infections that were health care− associated community-onset did not change significantly over the 4 Skin or soft tissue infection 105 (7) 88 (7) 95 (7) 91 (8) 
(7)
.50
Bone or joint infection 104 (7) 94 (7) 111 (9) 104 (9) 
(8)
.07
Urinary tract infection 81 (5) 62 (5) 73 (6) 54 (5 years, but the percentage of overall infections that were hospital-onset decreased from 26% to 23% over the period (P=.002) while the percentage of infections that were communityassociated increased from 17% to 19% (P = .01). Overall, 17 508 cases were either hospital-onset or health careassociated community-onset and were included in this analysis. The mean age of case-patients with these infections was 61 years and did not vary significantly over time. Similarly, the age distribution in the catchment area did not change significantly over the study period.
Most health care-associated infections (ie, hospital-onset or health careassociated community-onset) 15 458 (88%), involved a positive blood culture and were classified as a BSI (4496 were hospital-onset and 10 962 were health care-associated communityonset 
Invasive MRSA Infection Incidence
The actual case counts and pooled mean rates of invasive MRSA infections decreased incrementally each year in all categories except among patients undergoing dialysis where the largest decrease was in 2008 (TABLE 2). The modeled incidence, adjusted for age and race, of hospitalonset invasive MRSA infections significantly decreased 9.4% per year from 2005 through 2008; while there was a significant 5.7% decrease per year in the modeled incidence of health careassociated community-onset infections (TABLE 3) . This would equate to about a 28% decrease in all hospital-onset invasive MRSA infections and about a 17% decrease in all invasive health care-associated community-onset infections over the 4-year period. Decreases in crude incidence of invasive MRSA infection over the study period were apparent across virtually all age, sex, and race categories (TABLE 4). A subset analysis limited to BSIs demonstrated a larger decrease in the modeled yearly incidence rates of both hospital-onset (−11.2%) and health careassociated community-onset (−6.6%) BSIs (Table 3 ). This would equate to about a 34% decrease in all hospitalonset MRSA BSIs and about a 20% decrease in all health care-associated community-onset BSIs over the 4-year period.
Because rates of invasive MRSA infections are much higher among patients undergoing dialysis, 15 we evaluated changes in incidence of MRSA BSIs among this subgroup. Unadjusted incidence rates of health care-associated community-onset MRSA BSIs decreased 6.4% per year (Table 3) The changes in invasive hospitalonset and health care-associated community-onset MRSA infections stratified by sites are shown in the FIGURE. Seven of 9 sites had a statistically significant decrease in modeled hospitalonset invasive MRSA infections over the period. For health care-associated community-onset invasive MRSA infections, 8 sites demonstrated a decrease (6 statistically significant) and 1 demonstrated a significant increase over the period. The rates of invasive MRSA infections stratified by site, year, and epi- demiological class are shown in the eTable (available at http://www.jama .com).
COMMENT
Since 2005, when population-based estimates of invasive MRSA infections first became available, the incidence of invasive health care-associated MRSA infections has decreased. The annualized decrease in incidence was greatest for hospital-onset infections (9.4% per year). Furthermore, there was a yearly 5.7% decrease in infections among patients who had onset of their infection outside the hospital but who had recent exposure to health care delivery. This would translate to about a 28% and 17% decrease in hospital-onset and health care-associated communityonset invasive MRSA infections over the 4-year study period, respectively. Larger decreases were seen among patients with BSIs. In addition, although rates of invasive MRSA BSIs among patients who had undergone dialysis within the previous year were high, there was a comparable proportionate decrease in these infections among this group. Our findings complement those from several smaller studies of infection prevention interventions, which demonstrate decreases in MRSA infections at individual or small collections of facilities. 4 On a national scale in the United States, Burton and colleagues described a significant decrease in MRSA central lineassociated BSIs reported from intensive care units from 1997 through 2007. 10 Those data, however, do not reflect health care-associated MRSA infections that might manifest after the patient is discharged. The data presented herein complement and support the findings presented in that evaluation and also expand on it by demonstrating a decrease in invasive MRSA infections, not only among patients in hospitals but also among outpatients with health care exposure.
Although the reasons for the observed decrease in incidence of invasive health care-associated MRSA infections is not known, a number of factors might have contributed, including the dissemination of MRSA prevention practices in many US hospitals. Two groups, including the CDC's Healthcare Infection Control Practices Advisory Committee, have produced recommendations for preventing health care transmission of multidrug-resistant organisms such as MRSA. 16, 17 These recommendations are supported by studies that have shown decreases in rates of MRSA infections following implementation of MRSA prevention practices, usually at individual or small groups of facilities. 4, 5, 9 In our study, the fact that the observed reductions were greater among hospital-onset infections than health care-associated community-onset infections suggests that prevention practices in acute care settings contributed to these decreases. In addition, colonized patients discharged from acute care settings appear to be at high risk of subsequent MRSA infections as outpatients. 18 Interventions that successfully decrease MRSA transmission in hospitals might therefore contribute to the observed decrease in rates of health care-associated community-onset infections.
Because 86% of the invasive MRSA infections reported to this surveillance system were BSIs, much of the estimated reduction in these infections might have been due to the dissemination of inpatient central lineassociated BSI prevention efforts rather than MRSA-specific prevention efforts. Examples of such initiatives on a regional scale occurring outside of our surveillance program include the Michigan Keystone intensive care unit project and the Pittsburgh Regional Health Initiative project. 19, 20 One of the strengths of the Emerging Infections Program/Active Bacterial Core surveillances MRSA surveillance system is that rates are populationbased, reflecting the burden of invasive MRSA infections in a diverse set of geographic areas and across a wide variety of health care and community settings. However, because the total population of the catchment areas is used as the denominator in these incidence measures and not hospital patientdays, shorter lengths of stay could reclassify some infections from hospitalonset to community-onset. Although the average length of stay in the United States decreased from 7.8 days in 1970 to 4.8 days in 2006, it has remained stable at 4.8 to 4.9 days during the years 2000-2006. 21, 22 We are unable to determine the average length of stay during 2005-2008 for our surveillance area. If patient length of stay did decrease, the incidence of hospital-onset infections might decrease simply because more of these infections occur after patients are discharged. However, we also found significant, albeit smaller reductions, in the incidence of health careassociated, community-onset infections suggesting shorter length of stays does not explain all the observed changes in incidence rates.
One other possible reason for the decreases in incidence described herein is a change in the strains associated with invasive MRSA infections. USA300 MRSA strains have emerged as a common cause of infections in the community. 23, 24 These isolates are also being recognized as a cause of infections in hospitals. [25] [26] [27] Previous analysis of isolates from 2005 and 2006 submitted from the surveillance MRSA program found that 18% of the isolates from a sample of hospital-onset infections were USA300. 26 Further analysis of isolates though 2008 has shown similar proportions of USA300 strains among hospital-onset infections. 28 The absence of major changes in the composition of strains associated with health careassociated invasive MRSA infections during the study period makes shifting strain composition an unlikely cause of the observed decreases in incidence. In addition, although USA300 strains are a well-described cause of invasive infections, 25, [29] [30] [31] there are no con-vincing data available that USA300 strains have a higher or lower propensity to cause invasive disease than other strains in the hospital setting. We were able to evaluate changes in invasive MRSA infection incidence specifically among the population of patients undergoing dialysis. These patients have already been shown to be at more than 100 times the risk of acquiring invasive MRSA infections than the general population. 15 The decrease in MRSA BSIs among dialysis patients that we observed is encouraging although most of this decrease was observed in 2008; ongoing analysis will be needed to determine whether this decrease persists.
Most invasive MRSA infections in this evaluation had their onset outside of acute-care hospitals in patients with previous health care exposures such as dialysis or recent hospitalizations. Preventing health care-associated infections in these settings is a priority for the CDC. Further work is needed to understand the epidemiology of these infections among these groups, to guide the development and implementation of interventions aimed at prevention.
This report is subject to several limitations. First, data from the Emerging Infections Program/Active Bacterial Core surveillance system represent data from 9 metropolitan areas. These data are not nationally representative but do represent 1 of the largest populations evaluated for changes in incidence of invasive MRSA in the United States. Second, this surveillance system does not include nonresidents of the catchment area, so facility-specific incidence rates cannot be determined. For this reason, we are unable to use facility patient-days as a denominator to calculate valid facility-specific or overall incidence rates per patient-day. Third, the denominators used for both the primary and dialysis analyses are estimates and may not completely reflect the total number of patients nor their exact contribution in person-time; however, these issues would be unlikely to have changed over the study period.
Despite these limitations, this evaluation demonstrates that the incidence of hospital-onset and health careassociated community-onset invasive MRSA infections has decreased dramatically and significantly in this large geographically diverse population. Taken together with data from more than 600 intensive care units nationwide, 10 these findings suggest that there is a real decrease in MRSA infection rates among patients in US hospitals. As highlighted in the recently finalized US Department of Health and Human Services Action Plan to Prevent Healthcare-Associated Infections, 3 prevention of invasive MRSA infections is a national priority. Although these data suggest progress has occurred in preventing health care-associated MRSA infections, more challenges remain. Increasing adherence to existing recommendations and addressing MRSA transmission and prevention beyond inpatient settings are challenges that will require further effort and investigation if eliminating the goal of preventable health care-associated invasive MRSA infections is to be attained.
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